Cipro

Overview

ciprofloxacin

fluoroquinolone

• OAT1 substrate
• OAT3 substrate
• CYP1A2 inhibitor, strong
• CYP3A4 inhibitor, moderate
• affected by altered gastrointestinal motility
• alters GI flora
• binds to anion exchange resin/polymer
• binds to cation exchange resin/polymer
• binds to polyvalent cations
• hyperglycemic effects
• hypoglycemic effects
• impairs immunomodulatory bacterial infective agent
• lowers seizure threshold
• peripheral neuropathy
• photosensitivity
• prolongs QT interval (conditional)
• pseudotumor cerebri
• urine pH sensitive

Contraindicated

• cisapride
Cipro (ciprofloxacin)

+

cisapride

1 interaction

Contraindicated

ciprofloxacin + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• eliglustat
Cipro (ciprofloxacin)

+

eliglustat

1 interaction

Contraindicated

ciprofloxacin + eliglustat

CYP2D6 EM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, avoid combo; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• fezolinetant
Cipro (ciprofloxacin)

+

fezolinetant

1 interaction

Contraindicated

ciprofloxacin + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metab. inhibited)

• flibanserin
Cipro (ciprofloxacin)

+

flibanserin

1 interaction

Contraindicated

ciprofloxacin + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited)

• lomitapide
Cipro (ciprofloxacin)

+

lomitapide

1 interaction

Contraindicated

ciprofloxacin + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• pimozide
Cipro (ciprofloxacin)

+

pimozide

1 interaction

Contraindicated

ciprofloxacin + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• thioridazine
Cipro (ciprofloxacin)

+

thioridazine

1 interaction

Contraindicated

ciprofloxacin + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tizanidine
Cipro (ciprofloxacin)

+

tizanidine

1 interaction

Contraindicated

ciprofloxacin + tizanidine

contraindicated: combo may incr. tizanidine levels, risk of hypotension (incl. orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

Avoid/Use Alternative

• aldesleukin
Cipro (ciprofloxacin)

+

aldesleukin

1 interaction

Avoid/Use Alternative

ciprofloxacin + aldesleukin

avoid combo: combo may incr. risk of seizures (additive effects)

• alfentanil
Cipro (ciprofloxacin)

+

alfentanil

1 interaction

Avoid/Use Alternative

ciprofloxacin + alfentanil

use alternative or monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• alosetron
Cipro (ciprofloxacin)

+

alosetron

1 interaction

Avoid/Use Alternative

ciprofloxacin + alosetron

avoid combo: combo may incr. alosetron levels, risk of adverse effects (hepatic metab. inhibited)

• alprazolam
Cipro (ciprofloxacin)

+

alprazolam

1 interaction

Avoid/Use Alternative

ciprofloxacin + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• amifampridine
Cipro (ciprofloxacin)

+

amifampridine

1 interaction

Avoid/Use Alternative

ciprofloxacin + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• aminolevulinic acid topical
Cipro (ciprofloxacin)

+

aminolevulinic acid topical

1 interaction

Avoid/Use Alternative

ciprofloxacin + aminolevulinic acid topical

avoid combo: combo may incr. risk of photosensitivity rxn (additive effects)

• aminophylline
Cipro (ciprofloxacin)

+

aminophylline

1 interaction

Avoid/Use Alternative

ciprofloxacin + aminophylline

use alternative or monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited; aminophylline converted to theophylline)

• amiodarone
Cipro (ciprofloxacin)

+

amiodarone

1 interaction

Avoid/Use Alternative

ciprofloxacin + amiodarone

avoid combo: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• aprepitant
Cipro (ciprofloxacin)

+

aprepitant

1 interaction

Avoid/Use Alternative

ciprofloxacin + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• arsenic trioxide
Cipro (ciprofloxacin)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

ciprofloxacin + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Cipro (ciprofloxacin)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

ciprofloxacin + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• asenapine
Cipro (ciprofloxacin)

+

asenapine

1 interaction

Avoid/Use Alternative

ciprofloxacin + asenapine

avoid combo: combo may incr. asenapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• avapritinib
Cipro (ciprofloxacin)

+

avapritinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + avapritinib

GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• azithromycin
Cipro (ciprofloxacin)

+

azithromycin

1 interaction

Avoid/Use Alternative

ciprofloxacin + azithromycin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• BCG live intravesical
Cipro (ciprofloxacin)

+

BCG live intravesical

1 interaction

Avoid/Use Alternative

ciprofloxacin + BCG live intravesical

avoid combo: combo may decr. BCG live intravesical efficacy (antibacterial effect may interfere w/ BCG activity)

• bedaquiline
Cipro (ciprofloxacin)

+

bedaquiline

1 interaction

Avoid/Use Alternative

ciprofloxacin + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bendamustine
Cipro (ciprofloxacin)

+

bendamustine

1 interaction

Avoid/Use Alternative

ciprofloxacin + bendamustine

consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• bosentan
Cipro (ciprofloxacin)

+

bosentan

1 interaction

Avoid/Use Alternative

ciprofloxacin + bosentan

avoid combo if also combined w/ CYP2C9 inhibitor; otherwise caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic metab. inhibited)

• bosutinib
Cipro (ciprofloxacin)

+

bosutinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• bremelanotide
Cipro (ciprofloxacin)

+

bremelanotide

1 interaction

Avoid/Use Alternative

ciprofloxacin + bremelanotide

avoid combo w/ oral ciprofloxacin: combo may decr. ciprofloxacin levels, efficacy (absorption delayed/reduced)

• brigatinib
Cipro (ciprofloxacin)

+

brigatinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited)

• buspirone
Cipro (ciprofloxacin)

+

buspirone

1 interaction

Avoid/Use Alternative

ciprofloxacin + buspirone

consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metab. inhibited)

• cholera vaccine, live
Cipro (ciprofloxacin)

+

cholera vaccine, live

1 interaction

Avoid/Use Alternative

ciprofloxacin + cholera vaccine, live

avoid vaccine until at least 14 days after ciprofloxacin course complete: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• clarithromycin
Cipro (ciprofloxacin)

+

clarithromycin

1 interaction

Avoid/Use Alternative

ciprofloxacin + clarithromycin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cobimetinib
Cipro (ciprofloxacin)

+

cobimetinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + cobimetinib

avoid combo or decr. cobimetinib dose to 20 mg/day and limit tx w/ ciprofloxacin to 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• codeine
Cipro (ciprofloxacin)

+

codeine

1 interaction

Avoid/Use Alternative

ciprofloxacin + codeine

use alternative or monitor resp. rate; consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

• colchicine
Cipro (ciprofloxacin)

+

colchicine

1 interaction

Avoid/Use Alternative

ciprofloxacin + colchicine

CV RISK REDUCTION: avoid combo in pts w/ renal or hepatic impairment; otherwise, monitor CK, myopathy s/sx; GOUT or FMF: use alternative or decr. colchicine dose based on indication during and x14 days after ciprofloxacin use as follows: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited)

• conivaptan
Cipro (ciprofloxacin)

+

conivaptan

1 interaction

Avoid/Use Alternative

ciprofloxacin + conivaptan

consider alternative: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metab. inhibited)

• crizotinib
Cipro (ciprofloxacin)

+

crizotinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + crizotinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• defactinib
Cipro (ciprofloxacin)

+

defactinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metab. inhibited)

• desipramine
Cipro (ciprofloxacin)

+

desipramine

1 interaction

Avoid/Use Alternative

ciprofloxacin + desipramine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dichlorphenamide
Cipro (ciprofloxacin)

+

dichlorphenamide

1 interaction

Avoid/Use Alternative

ciprofloxacin + dichlorphenamide

avoid combo: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may incr. risk of crystalluria (renal transport possibly inhibited; decreased ciprofloxacin solubility at higher urine pH)

• dihydrocodeine
Cipro (ciprofloxacin)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

ciprofloxacin + dihydrocodeine

use alternative or monitor resp. rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite dihydromorphine)

• dihydroergotamine
Cipro (ciprofloxacin)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

ciprofloxacin + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• disopyramide
Cipro (ciprofloxacin)

+

disopyramide

1 interaction

Avoid/Use Alternative

ciprofloxacin + disopyramide

avoid combo: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dofetilide
Cipro (ciprofloxacin)

+

dofetilide

1 interaction

Avoid/Use Alternative

ciprofloxacin + dofetilide

use alternative or monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited; additive effects)

• domperidone
Cipro (ciprofloxacin)

+

domperidone

1 interaction

Avoid/Use Alternative

ciprofloxacin + domperidone

avoid combo: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dordaviprone
Cipro (ciprofloxacin)

+

dordaviprone

1 interaction

Avoid/Use Alternative

ciprofloxacin + dordaviprone

use alternative or monitor ECG, electrolytes; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 500 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• doxorubicin
Cipro (ciprofloxacin)

+

doxorubicin

1 interaction

Avoid/Use Alternative

ciprofloxacin + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• dronedarone
Cipro (ciprofloxacin)

+

dronedarone

1 interaction

Avoid/Use Alternative

ciprofloxacin + dronedarone

avoid combo: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• duloxetine
Cipro (ciprofloxacin)

+

duloxetine

1 interaction

Avoid/Use Alternative

ciprofloxacin + duloxetine

avoid combo: combo may incr. duloxetine levels, risk of adverse effects (hepatic metab. inhibited)

• elacestrant
Cipro (ciprofloxacin)

+

elacestrant

1 interaction

Avoid/Use Alternative

ciprofloxacin + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metab. inhibited)

• encorafenib
Cipro (ciprofloxacin)

+

encorafenib

1 interaction

Avoid/Use Alternative

ciprofloxacin + encorafenib

use alternative or monitor ECG, electrolytes; decr. encorafenib 450 mg dose to 225 mg, decr. 300 mg dose to 150 mg, decr. 225 mg dose to 75 mg, and decr. 150 mg dose to 75 mg: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ensartinib
Cipro (ciprofloxacin)

+

ensartinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metab. possibly inhibited)

• entrectinib
Cipro (ciprofloxacin)

+

entrectinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + entrectinib

PEDS PTS w/ ENTRECTINIB START DOSE <200 mg/day: avoid combo; ADULT AND PEDS PTS >2yo: use alternative or monitor ECG, CBC, limit coadmin. to 14 days or less and decr. entrectinib dose as follows: if entrectinib start dose 200 mg qd, decr. to 50 mg qd; if entrectinib start dose 300 mg qd, decr. to 100 mg qd; if entrectinib start dose 400 or 600 mg qd, decr. to 200 mg qd: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ephedra
Cipro (ciprofloxacin)

+

ephedra

1 interaction

Avoid/Use Alternative

ciprofloxacin + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ergotamine
Cipro (ciprofloxacin)

+

ergotamine

1 interaction

Avoid/Use Alternative

ciprofloxacin + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• erlotinib
Cipro (ciprofloxacin)

+

erlotinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + erlotinib

use alternative or consider decr. erlotinib dose by 50 mg/day decrements: combo may incr. erlotinib levels, risk of adverse effects (hepatic metab. inhibited)

• erythromycin
Cipro (ciprofloxacin)

+

erythromycin

1 interaction

Avoid/Use Alternative

ciprofloxacin + erythromycin

avoid combo: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• etrasimod
Cipro (ciprofloxacin)

+

etrasimod

1 interaction

Avoid/Use Alternative

ciprofloxacin + etrasimod

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited)

• fecal microbiota, live
Cipro (ciprofloxacin)

+

fecal microbiota, live

1 interaction

Avoid/Use Alternative

ciprofloxacin + fecal microbiota, live

ORAL MICROBIOTA: avoid combo; RECTAL MICROBIOTA: avoid combo up to 8wk after admin.: combo may decr. gut microbiota restoration (antibiotic effects)

• fentanyl
Cipro (ciprofloxacin)

+

fentanyl

1 interaction

Avoid/Use Alternative

ciprofloxacin + fentanyl

use alternative or monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• fexinidazole
Cipro (ciprofloxacin)

+

fexinidazole

1 interaction

Avoid/Use Alternative

ciprofloxacin + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after ciprofloxacin D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. fexinidazole active metabolite levels, efficacy (renal transport possibly inhibited, additive effects; hepatic metab. inhibited, decr. conversion to active metabolites)

• fosaprepitant
Cipro (ciprofloxacin)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

ciprofloxacin + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• haloperidol
Cipro (ciprofloxacin)

+

haloperidol

1 interaction

Avoid/Use Alternative

ciprofloxacin + haloperidol

use alternative or monitor ECG: combo may incr. haloperidol levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• hydrocodone
Cipro (ciprofloxacin)

+

hydrocodone

1 interaction

Avoid/Use Alternative

ciprofloxacin + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• hydroxychloroquine
Cipro (ciprofloxacin)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

ciprofloxacin + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• ibutilide
Cipro (ciprofloxacin)

+

ibutilide

1 interaction

Avoid/Use Alternative

ciprofloxacin + ibutilide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iohexol
Cipro (ciprofloxacin)

+

iohexol

1 interaction

Avoid/Use Alternative

ciprofloxacin + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• ivabradine
Cipro (ciprofloxacin)

+

ivabradine

1 interaction

Avoid/Use Alternative

ciprofloxacin + ivabradine

avoid combo: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Cipro (ciprofloxacin)

+

ivosidenib

1 interaction

Avoid/Use Alternative

ciprofloxacin + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ixabepilone
Cipro (ciprofloxacin)

+

ixabepilone

1 interaction

Avoid/Use Alternative

ciprofloxacin + ixabepilone

consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• lefamulin
Cipro (ciprofloxacin)

+

lefamulin

1 interaction

Avoid/Use Alternative

ciprofloxacin + lefamulin

use alternative or monitor ECG: combo w/ oral lefamulin may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo w/ IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• lemborexant
Cipro (ciprofloxacin)

+

lemborexant

1 interaction

Avoid/Use Alternative

ciprofloxacin + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• levoketoconazole
Cipro (ciprofloxacin)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

ciprofloxacin + levoketoconazole

consider alternative x2wk before and during levoketoconazole tx; otherwise, monitor ECG: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lonafarnib
Cipro (ciprofloxacin)

+

lonafarnib

1 interaction

Avoid/Use Alternative

ciprofloxacin + lonafarnib

use alternative or monitor HR, ECG, electrolytes, especially during first week when adding lonafarnib to existing ciprofloxacin tx: combo may incr. lonafarnib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lovastatin
Cipro (ciprofloxacin)

+

lovastatin

1 interaction

Avoid/Use Alternative

ciprofloxacin + lovastatin

use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Cipro (ciprofloxacin)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

ciprofloxacin + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• macitentan
Cipro (ciprofloxacin)

+

macitentan

1 interaction

Avoid/Use Alternative

ciprofloxacin + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metab. inhibited)

• meperidine
Cipro (ciprofloxacin)

+

meperidine

1 interaction

Avoid/Use Alternative

ciprofloxacin + meperidine

use alternative or monitor resp. rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• methadone
Cipro (ciprofloxacin)

+

methadone

1 interaction

Avoid/Use Alternative

ciprofloxacin + methadone

use alternative or monitor resp. rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• methotrexate
Cipro (ciprofloxacin)

+

methotrexate

1 interaction

Avoid/Use Alternative

ciprofloxacin + methotrexate

if oral methotrexate use, consider alternative or monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects; may decr. methotrexate active metabolite levels, efficacy (decreased absorption, renal excretion possibly decreased; intestinal metab. inhibited, decr. conversion to active metabolite)

• methylergonovine
Cipro (ciprofloxacin)

+

methylergonovine

1 interaction

Avoid/Use Alternative

ciprofloxacin + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• midazolam
Cipro (ciprofloxacin)

+

midazolam

1 interaction

Avoid/Use Alternative

ciprofloxacin + midazolam

avoid combo if midazolam nasal use; otherwise, monitor resp. rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• mobocertinib
Cipro (ciprofloxacin)

+

mobocertinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + mobocertinib

use alternative or monitor ECG, electrolytes; decr. mobocertinib dose as follows: if taking 160 mg, decr. dose to 80 mg; if taking 120 mg, decr. dose to 40 mg, if taking 80 mg, decr. dose to 40 mg: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• naloxegol
Cipro (ciprofloxacin)

+

naloxegol

1 interaction

Avoid/Use Alternative

ciprofloxacin + naloxegol

use alternative or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metab. inhibited)

• neratinib
Cipro (ciprofloxacin)

+

neratinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metab. inhibited)

• nirogacestat
Cipro (ciprofloxacin)

+

nirogacestat

1 interaction

Avoid/Use Alternative

ciprofloxacin + nirogacestat

avoid combo: combo may incr. nirogacestat levels, risk of hypophosphatemia, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Cipro (ciprofloxacin)

+

nisoldipine

1 interaction

Avoid/Use Alternative

ciprofloxacin + nisoldipine

consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• olaparib
Cipro (ciprofloxacin)

+

olaparib

1 interaction

Avoid/Use Alternative

ciprofloxacin + olaparib

use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• oliceridine
Cipro (ciprofloxacin)

+

oliceridine

1 interaction

Avoid/Use Alternative

ciprofloxacin + oliceridine

use alternative or monitor resp. rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• omaveloxolone
Cipro (ciprofloxacin)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

ciprofloxacin + omaveloxolone

use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects (hepatic metab. inhibited)

• oxycodone
Cipro (ciprofloxacin)

+

oxycodone

1 interaction

Avoid/Use Alternative

ciprofloxacin + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• paliperidone
Cipro (ciprofloxacin)

+

paliperidone

1 interaction

Avoid/Use Alternative

ciprofloxacin + paliperidone

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palovarotene
Cipro (ciprofloxacin)

+

palovarotene

1 interaction

Avoid/Use Alternative

ciprofloxacin + palovarotene

use alternative or monitor pseudotumor cerebri s/sx; decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of intracranial HTN, papilledema, other adverse effects (hepatic metab. inhibited, additive effects)

• pemigatinib
Cipro (ciprofloxacin)

+

pemigatinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• pexidartinib
Cipro (ciprofloxacin)

+

pexidartinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + pexidartinib

use alternative or monitor LFTs, decr. pexidartinib dose as follows: if on pexidartinib 500 mg/day or 375 mg/day, decr. to 125 mg bid; if on pexidartinib 250 mg/day, decr. to 125 mg qd: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• pirfenidone
Cipro (ciprofloxacin)

+

pirfenidone

1 interaction

Avoid/Use Alternative

ciprofloxacin + pirfenidone

avoid combo if also combined w/ mod-strong CYP2C9, 2C19, 2D6, or 2E1 inhibitor; avoid combo w/ ciprofloxacin 1500 mg/day or decr. pirfenidone dose to 534 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• pomalidomide
Cipro (ciprofloxacin)

+

pomalidomide

1 interaction

Avoid/Use Alternative

ciprofloxacin + pomalidomide

use alternative or monitor CBC; decr. pomalidomide dose to 2mg: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• porfimer
Cipro (ciprofloxacin)

+

porfimer

1 interaction

Avoid/Use Alternative

ciprofloxacin + porfimer

avoid combo: combo may incr. risk of photosensitivity rxn (additive effects)

• pralsetinib
Cipro (ciprofloxacin)

+

pralsetinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• procainamide
Cipro (ciprofloxacin)

+

procainamide

1 interaction

Avoid/Use Alternative

ciprofloxacin + procainamide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Cipro (ciprofloxacin)

+

propafenone

1 interaction

Avoid/Use Alternative

ciprofloxacin + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• quinidine (antiarrhythmic)
Cipro (ciprofloxacin)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

ciprofloxacin + quinidine (antiarrhythmic)

avoid combo: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quizartinib
Cipro (ciprofloxacin)

+

quizartinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• repotrectinib
Cipro (ciprofloxacin)

+

repotrectinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + repotrectinib

avoid combo; D/C ciprofloxacin 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• rilzabrutinib
Cipro (ciprofloxacin)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + rilzabrutinib

avoid combo if ciprofloxacin use greater than 7 days; use alternative or hold rilzabrutinib if ciprofloxacin use less than 7 days: combo may incr. rilzabrutinib levels, risk of adverse effects (hepatic metab. inhibited)

• rivaroxaban
Cipro (ciprofloxacin)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

ciprofloxacin + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• selpercatinib
Cipro (ciprofloxacin)

+

selpercatinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• selumetinib
Cipro (ciprofloxacin)

+

selumetinib

1 interaction

Avoid/Use Alternative

ciprofloxacin + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• simvastatin
Cipro (ciprofloxacin)

+

simvastatin

1 interaction

Avoid/Use Alternative

ciprofloxacin + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• siponimod
Cipro (ciprofloxacin)

+

siponimod

1 interaction

Avoid/Use Alternative

ciprofloxacin + siponimod

if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. siponimod levels, risk of adverse effects (hepatic metab. inhibited)

• sodium bicarbonate
Cipro (ciprofloxacin)

+

sodium bicarbonate

1 interaction

Avoid/Use Alternative

ciprofloxacin + sodium bicarbonate

avoid combo: combo may incr. risk of crystalluria (decreased ciprofloxacin solubility at higher urine pH)

• sodium citrate
Cipro (ciprofloxacin)

+

sodium citrate

1 interaction

Avoid/Use Alternative

ciprofloxacin + sodium citrate

avoid combo: combo may incr. risk of crystalluria (decreased ciprofloxacin solubility at higher urine pH)

• sonidegib
Cipro (ciprofloxacin)

+

sonidegib

1 interaction

Avoid/Use Alternative

ciprofloxacin + sonidegib

avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metab. inhibited)

• sotalol
Cipro (ciprofloxacin)

+

sotalol

1 interaction

Avoid/Use Alternative

ciprofloxacin + sotalol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sufentanil
Cipro (ciprofloxacin)

+

sufentanil

1 interaction

Avoid/Use Alternative

ciprofloxacin + sufentanil

consider alternative or monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tasimelteon
Cipro (ciprofloxacin)

+

tasimelteon

1 interaction

Avoid/Use Alternative

ciprofloxacin + tasimelteon

avoid combo: combo may incr. tasimelteon levels, risk of adverse effects (hepatic metab. inhibited)

• tazemetostat
Cipro (ciprofloxacin)

+

tazemetostat

1 interaction

Avoid/Use Alternative

ciprofloxacin + tazemetostat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• theophylline
Cipro (ciprofloxacin)

+

theophylline

1 interaction

Avoid/Use Alternative

ciprofloxacin + theophylline

use alternative or monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metab. inhibited)

• tolvaptan
Cipro (ciprofloxacin)

+

tolvaptan

1 interaction

Avoid/Use Alternative

ciprofloxacin + tolvaptan

HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metab. inhibited)

• topiramate
Cipro (ciprofloxacin)

+

topiramate

1 interaction

Avoid/Use Alternative

ciprofloxacin + topiramate

avoid combo: combo may alter seizure control; may incr. risk of crystalluria (antagonistic effects, ciprofloxacin may decr. seizure threshold; decreased ciprofloxacin solubility at higher urine pH)

• toremifene
Cipro (ciprofloxacin)

+

toremifene

1 interaction

Avoid/Use Alternative

ciprofloxacin + toremifene

use alternative or monitor ECG: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tramadol
Cipro (ciprofloxacin)

+

tramadol

1 interaction

Avoid/Use Alternative

ciprofloxacin + tramadol

use alternative or monitor resp. rate, ECG, consider decr. tramadol dose: combo may incr. tramadol and active metabolite levels, risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite; additive effects)

• tretinoin
Cipro (ciprofloxacin)

+

tretinoin

1 interaction

Avoid/Use Alternative

ciprofloxacin + tretinoin

avoid combo: combo may incr. tretinoin levels, risk of intracranial HTN, papilledema, other adverse effects (hepatic metab. inhibited, additive effects)

• typhoid vaccine, live
Cipro (ciprofloxacin)

+

typhoid vaccine, live

1 interaction

Avoid/Use Alternative

ciprofloxacin + typhoid vaccine, live

avoid vaccine course during and w/in 72h of ciprofloxacin use; if possible, delay ciprofloxacin until at least 72h after last vaccine dose: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• vandetanib
Cipro (ciprofloxacin)

+

vandetanib

1 interaction

Avoid/Use Alternative

ciprofloxacin + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vardenafil
Cipro (ciprofloxacin)

+

vardenafil

1 interaction

Avoid/Use Alternative

ciprofloxacin + vardenafil

max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• venetoclax
Cipro (ciprofloxacin)

+

venetoclax

1 interaction

Avoid/Use Alternative

ciprofloxacin + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• vorasidenib
Cipro (ciprofloxacin)

+

vorasidenib

1 interaction

Avoid/Use Alternative

ciprofloxacin + vorasidenib

use alternative: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metab. inhibited)

• ziprasidone
Cipro (ciprofloxacin)

+

ziprasidone

1 interaction

Avoid/Use Alternative

ciprofloxacin + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• zolpidem
Cipro (ciprofloxacin)

+

zolpidem

1 interaction

Avoid/Use Alternative

ciprofloxacin + zolpidem

avoid combo: combo may incr. zolpidem levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

Monitor/Modify Tx

• abemaciclib
Cipro (ciprofloxacin)

+

abemaciclib

1 interaction

Monitor/Modify Tx

ciprofloxacin + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Cipro (ciprofloxacin)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• acarbose
Cipro (ciprofloxacin)

+

acarbose

1 interaction

Monitor/Modify Tx

ciprofloxacin + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, fluoroquinolones may alter blood glucose)

• acitretin
Cipro (ciprofloxacin)

+

acitretin

1 interaction

Monitor/Modify Tx

ciprofloxacin + acitretin

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema, photosensitivity rxn (additive effects)

• adagrasib
Cipro (ciprofloxacin)

+

adagrasib

1 interaction

Monitor/Modify Tx

ciprofloxacin + adagrasib

monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• alfuzosin
Cipro (ciprofloxacin)

+

alfuzosin

1 interaction

Monitor/Modify Tx

ciprofloxacin + alfuzosin

monitor BP, ECG: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• alogliptin
Cipro (ciprofloxacin)

+

alogliptin

1 interaction

Monitor/Modify Tx

ciprofloxacin + alogliptin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• aluminum hydroxide
Cipro (ciprofloxacin)

+

aluminum hydroxide

1 interaction

Monitor/Modify Tx

ciprofloxacin + aluminum hydroxide

give oral ciprofloxacin at least 2h before or 6h after aluminum hydroxide: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• anagrelide
Cipro (ciprofloxacin)

+

anagrelide

1 interaction

Monitor/Modify Tx

ciprofloxacin + anagrelide

monitor ECG, consider decr. anagrelide dose: combo may incr. anagrelide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• apalutamide
Cipro (ciprofloxacin)

+

apalutamide

1 interaction

Monitor/Modify Tx

ciprofloxacin + apalutamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apixaban
Cipro (ciprofloxacin)

+

apixaban

1 interaction

Monitor/Modify Tx

ciprofloxacin + apixaban

monitor bleeding s/sx, especially if also combined w/ P-gp inhibitor: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• apomorphine
Cipro (ciprofloxacin)

+

apomorphine

1 interaction

Monitor/Modify Tx

ciprofloxacin + apomorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aripiprazole oral
Cipro (ciprofloxacin)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

ciprofloxacin + aripiprazole oral

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• atorvastatin
Cipro (ciprofloxacin)

+

atorvastatin

1 interaction

Monitor/Modify Tx

ciprofloxacin + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• avanafil
Cipro (ciprofloxacin)

+

avanafil

1 interaction

Monitor/Modify Tx

ciprofloxacin + avanafil

monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avatrombopag
Cipro (ciprofloxacin)

+

avatrombopag

1 interaction

Monitor/Modify Tx

ciprofloxacin + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• axitinib
Cipro (ciprofloxacin)

+

axitinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + axitinib

consider decr. axitinib dose: combo may incr. axitinib levels, risk of adverse effects (hepatic metab. inhibited)

• bempedoic acid
Cipro (ciprofloxacin)

+

bempedoic acid

1 interaction

Monitor/Modify Tx

ciprofloxacin + bempedoic acid

monitor tendon rupture s/sx: combo may incr. risk of tendon rupture (additive effects)

• bexagliflozin
Cipro (ciprofloxacin)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

ciprofloxacin + bexagliflozin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• brexpiprazole
Cipro (ciprofloxacin)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

ciprofloxacin + brexpiprazole

if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• bromocriptine
Cipro (ciprofloxacin)

+

bromocriptine

1 interaction

Monitor/Modify Tx

ciprofloxacin + bromocriptine

limit bromocriptine max dose to 1.6 mg/day and monitor glucose in type 2 diabetes mellitus pts; otherwise, caution advised: combo may incr. bromocriptine levels, risk of hypotension, other adverse effects; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (hepatic metab. inhibited; antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• budesonide
Cipro (ciprofloxacin)

+

budesonide

1 interaction

Monitor/Modify Tx

ciprofloxacin + budesonide

monitor hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, incl. Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metab. inhibited)

• bupropion
Cipro (ciprofloxacin)

+

bupropion

1 interaction

Monitor/Modify Tx

ciprofloxacin + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• butorphanol
Cipro (ciprofloxacin)

+

butorphanol

1 interaction

Monitor/Modify Tx

ciprofloxacin + butorphanol

monitor resp. rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• cabotegravir
Cipro (ciprofloxacin)

+

cabotegravir

1 interaction

Monitor/Modify Tx

ciprofloxacin + cabotegravir

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• cabozantinib
Cipro (ciprofloxacin)

+

cabozantinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + cabozantinib

monitor ECG, BP, bleeding s/sx: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• caffeine citrate
Cipro (ciprofloxacin)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

ciprofloxacin + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of cardiovascular and CNS stimulatory effects, toxicity (hepatic metab. inhibited)

• calcium acetate
Cipro (ciprofloxacin)

+

calcium acetate

1 interaction

Monitor/Modify Tx

ciprofloxacin + calcium acetate

give oral ciprofloxacin at least 2h before or 6h after calcium acetate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• calcium carbonate
Cipro (ciprofloxacin)

+

calcium carbonate

1 interaction

Monitor/Modify Tx

ciprofloxacin + calcium carbonate

give oral ciprofloxacin at least 2h before or 6h after calcium carbonate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• calcium citrate
Cipro (ciprofloxacin)

+

calcium citrate

1 interaction

Monitor/Modify Tx

ciprofloxacin + calcium citrate

give oral ciprofloxacin at least 2h before or 6h after calcium citrate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• calcium gluconate
Cipro (ciprofloxacin)

+

calcium gluconate

1 interaction

Monitor/Modify Tx

ciprofloxacin + calcium gluconate

give oral ciprofloxacin at least 2h before or 6h after oral calcium gluconate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• canagliflozin
Cipro (ciprofloxacin)

+

canagliflozin

1 interaction

Monitor/Modify Tx

ciprofloxacin + canagliflozin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• capivasertib
Cipro (ciprofloxacin)

+

capivasertib

1 interaction

Monitor/Modify Tx

ciprofloxacin + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• carbamazepine
Cipro (ciprofloxacin)

+

carbamazepine

1 interaction

Monitor/Modify Tx

ciprofloxacin + carbamazepine

monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects; may alter seizure control (hepatic metab. inhibited; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• cariprazine
Cipro (ciprofloxacin)

+

cariprazine

1 interaction

Monitor/Modify Tx

ciprofloxacin + cariprazine

if starting cariprazine tx, adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 1.5 mg qod, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 1.5 mg qod; if on stable cariprazine tx and starting ciprofloxacin, adjust cariprazine dose as follows: ALL INDICATIONS: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 1.5 mg qod; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• ceritinib
Cipro (ciprofloxacin)

+

ceritinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + ceritinib

monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• chloroquine
Cipro (ciprofloxacin)

+

chloroquine

1 interaction

Monitor/Modify Tx

ciprofloxacin + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Cipro (ciprofloxacin)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

ciprofloxacin + chlorpromazine

monitor ECG: combo may incr. chlorpromazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• chromium
Cipro (ciprofloxacin)

+

chromium

1 interaction

Monitor/Modify Tx

ciprofloxacin + chromium

give oral ciprofloxacin at least 2h before or 6h after chromium: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• cilostazol
Cipro (ciprofloxacin)

+

cilostazol

1 interaction

Monitor/Modify Tx

ciprofloxacin + cilostazol

decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metab. inhibited)

• citalopram
Cipro (ciprofloxacin)

+

citalopram

1 interaction

Monitor/Modify Tx

ciprofloxacin + citalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clofazimine
Cipro (ciprofloxacin)

+

clofazimine

1 interaction

Monitor/Modify Tx

ciprofloxacin + clofazimine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clomipramine
Cipro (ciprofloxacin)

+

clomipramine

1 interaction

Monitor/Modify Tx

ciprofloxacin + clomipramine

monitor ECG: combo may incr. clomipramine levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metab. inhibited, additive effects)

• clonazepam
Cipro (ciprofloxacin)

+

clonazepam

1 interaction

Monitor/Modify Tx

ciprofloxacin + clonazepam

monitor resp. rate: combo may incr. clonazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• clozapine
Cipro (ciprofloxacin)

+

clozapine

1 interaction

Monitor/Modify Tx

ciprofloxacin + clozapine

monitor ECG, BP, HR; decr. clozapine to 1/3 usual dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, seizures, other adverse effects (hepatic metab. inhibited, additive effects)

• colesevelam
Cipro (ciprofloxacin)

+

colesevelam

1 interaction

Monitor/Modify Tx

ciprofloxacin + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• copanlisib
Cipro (ciprofloxacin)

+

copanlisib

1 interaction

Monitor/Modify Tx

ciprofloxacin + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Cipro (ciprofloxacin)

+

cyclosporine

1 interaction

Monitor/Modify Tx

ciprofloxacin + cyclosporine

monitor cyclosporine levels, renal fxn, pseudotumor cerebri s/sx: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, intracranial HTN, papilledema, other adverse effects (hepatic metab. inhibited, additive effects)

• cysteamine
Cipro (ciprofloxacin)

+

cysteamine

1 interaction

Monitor/Modify Tx

ciprofloxacin + cysteamine

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• dapagliflozin
Cipro (ciprofloxacin)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

ciprofloxacin + dapagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, fluoroquinolones may alter blood glucose)

• daridorexant
Cipro (ciprofloxacin)

+

daridorexant

1 interaction

Monitor/Modify Tx

ciprofloxacin + daridorexant

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• dasatinib
Cipro (ciprofloxacin)

+

dasatinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + dasatinib

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• deflazacort
Cipro (ciprofloxacin)

+

deflazacort

1 interaction

Monitor/Modify Tx

ciprofloxacin + deflazacort

decr. deflazacort to 1/3 usual dose: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression (hepatic metab. inhibited)

• degarelix
Cipro (ciprofloxacin)

+

degarelix

1 interaction

Monitor/Modify Tx

ciprofloxacin + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• demeclocycline
Cipro (ciprofloxacin)

+

demeclocycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + demeclocycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• desflurane
Cipro (ciprofloxacin)

+

desflurane

1 interaction

Monitor/Modify Tx

ciprofloxacin + desflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Cipro (ciprofloxacin)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

ciprofloxacin + dexmedetomidine

monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Cipro (ciprofloxacin)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

ciprofloxacin + dexmedetomidine injection

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• diazoxide
Cipro (ciprofloxacin)

+

diazoxide

1 interaction

Monitor/Modify Tx

ciprofloxacin + diazoxide

HYPERPHAGIA USE: monitor glucose; see diazoxide choline pkg insert for wt-based dose adjustments; HYPOGLYCEMIA USE: monitor glucose: combo may incr. diazoxide levels, risk of hyperglycemia, other adverse effects (hepatic metab. inhibited)

• docetaxel
Cipro (ciprofloxacin)

+

docetaxel

1 interaction

Monitor/Modify Tx

ciprofloxacin + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, peripheral neuropathy, other adverse effects (hepatic metab. inhibited, additive effects)

• donepezil
Cipro (ciprofloxacin)

+

donepezil

1 interaction

Monitor/Modify Tx

ciprofloxacin + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxycycline
Cipro (ciprofloxacin)

+

doxycycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + doxycycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• droperidol
Cipro (ciprofloxacin)

+

droperidol

1 interaction

Monitor/Modify Tx

ciprofloxacin + droperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dulaglutide
Cipro (ciprofloxacin)

+

dulaglutide

1 interaction

Monitor/Modify Tx

ciprofloxacin + dulaglutide

monitor glucose: combo may decr. peak oral ciprofloxacin levels, efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects, fluoroquinolones may alter blood glucose)

• empagliflozin
Cipro (ciprofloxacin)

+

empagliflozin

1 interaction

Monitor/Modify Tx

ciprofloxacin + empagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, fluoroquinolones may alter blood glucose)

• epirubicin
Cipro (ciprofloxacin)

+

epirubicin

1 interaction

Monitor/Modify Tx

ciprofloxacin + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eplerenone
Cipro (ciprofloxacin)

+

eplerenone

1 interaction

Monitor/Modify Tx

ciprofloxacin + eplerenone

monitor potassium, Cr in 3-7 days after tx start; in post-MI CHF pts, max eplerenone dose 25 mg/day; in HTN pts, start eplerenone 25 mg qd, max dose 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, serious arrhythmias, other adverse effects (hepatic metab. inhibited)

• eravacycline
Cipro (ciprofloxacin)

+

eravacycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + eravacycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• erdafitinib
Cipro (ciprofloxacin)

+

erdafitinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + erdafitinib

monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• eribulin
Cipro (ciprofloxacin)

+

eribulin

1 interaction

Monitor/Modify Tx

ciprofloxacin + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ertugliflozin
Cipro (ciprofloxacin)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

ciprofloxacin + ertugliflozin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• estazolam
Cipro (ciprofloxacin)

+

estazolam

1 interaction

Monitor/Modify Tx

ciprofloxacin + estazolam

monitor resp. rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• estradiol (contraceptive)
Cipro (ciprofloxacin)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

ciprofloxacin + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• ethinyl estradiol (contraceptive)
Cipro (ciprofloxacin)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

ciprofloxacin + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• everolimus
Cipro (ciprofloxacin)

+

everolimus

1 interaction

Monitor/Modify Tx

ciprofloxacin + everolimus

BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: if also combined w/ P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated, monitor CBC; otherwise, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, monitor everolimus levels, CBC and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels, CBC; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• exenatide
Cipro (ciprofloxacin)

+

exenatide

1 interaction

Monitor/Modify Tx

ciprofloxacin + exenatide

monitor glucose; give oral ciprofloxacin at least 1h before twice daily exenatide; caution w/ weekly exenatide: combo may decr. peak ciprofloxacin levels, efficacy; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (absorption delayed, possibly decreased; additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• fedratinib
Cipro (ciprofloxacin)

+

fedratinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• felodipine
Cipro (ciprofloxacin)

+

felodipine

1 interaction

Monitor/Modify Tx

ciprofloxacin + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fenfluramine
Cipro (ciprofloxacin)

+

fenfluramine

1 interaction

Monitor/Modify Tx

ciprofloxacin + fenfluramine

if also combined w/ stiripentol, adjust max fenfluramine dose to 17 mg/day; otherwise, adjust max fenfluramine dose to 20 mg/day: combo may incr. fenfluramine levels, risk of adverse effects; may alter seizure control (hepatic metab. inhibited; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• ferric citrate
Cipro (ciprofloxacin)

+

ferric citrate

1 interaction

Monitor/Modify Tx

ciprofloxacin + ferric citrate

give oral ciprofloxacin at least 2h before or 2h after ferric citrate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• ferric maltol
Cipro (ciprofloxacin)

+

ferric maltol

1 interaction

Monitor/Modify Tx

ciprofloxacin + ferric maltol

give oral ciprofloxacin at least 4h before or 6h after ferric maltol: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• ferrous fumarate
Cipro (ciprofloxacin)

+

ferrous fumarate

1 interaction

Monitor/Modify Tx

ciprofloxacin + ferrous fumarate

give oral ciprofloxacin at least 2h before or 6h after ferrous fumarate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• ferrous gluconate
Cipro (ciprofloxacin)

+

ferrous gluconate

1 interaction

Monitor/Modify Tx

ciprofloxacin + ferrous gluconate

give oral ciprofloxacin at least 2h before or 6h after ferrous gluconate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• ferrous sulfate
Cipro (ciprofloxacin)

+

ferrous sulfate

1 interaction

Monitor/Modify Tx

ciprofloxacin + ferrous sulfate

give oral ciprofloxacin at least 2h before or 6h after ferrous sulfate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• finerenone
Cipro (ciprofloxacin)

+

finerenone

1 interaction

Monitor/Modify Tx

ciprofloxacin + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• flecainide
Cipro (ciprofloxacin)

+

flecainide

1 interaction

Monitor/Modify Tx

ciprofloxacin + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Cipro (ciprofloxacin)

+

fluconazole

1 interaction

Monitor/Modify Tx

ciprofloxacin + fluconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Cipro (ciprofloxacin)

+

fluorouracil

1 interaction

Monitor/Modify Tx

ciprofloxacin + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Cipro (ciprofloxacin)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

ciprofloxacin + fosphenytoin

monitor phenytoin levels: combo may incr. or decr. phenytoin levels, incr. risk of adverse effects or decr. efficacy; may alter seizure control (mechanism unknown, hepatic metab. possibly altered; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• futibatinib
Cipro (ciprofloxacin)

+

futibatinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• gemfibrozil
Cipro (ciprofloxacin)

+

gemfibrozil

1 interaction

Monitor/Modify Tx

ciprofloxacin + gemfibrozil

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• gepirone
Cipro (ciprofloxacin)

+

gepirone

1 interaction

Monitor/Modify Tx

ciprofloxacin + gepirone

monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• gilteritinib
Cipro (ciprofloxacin)

+

gilteritinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + gilteritinib

monitor ECG, electrolytes: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• glasdegib
Cipro (ciprofloxacin)

+

glasdegib

1 interaction

Monitor/Modify Tx

ciprofloxacin + glasdegib

monitor CBC, ECG: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• glimepiride
Cipro (ciprofloxacin)

+

glimepiride

1 interaction

Monitor/Modify Tx

ciprofloxacin + glimepiride

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• glipizide
Cipro (ciprofloxacin)

+

glipizide

1 interaction

Monitor/Modify Tx

ciprofloxacin + glipizide

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• glyburide
Cipro (ciprofloxacin)

+

glyburide

1 interaction

Monitor/Modify Tx

ciprofloxacin + glyburide

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects; fluoroquinolones may alter blood glucose)

• goserelin
Cipro (ciprofloxacin)

+

goserelin

1 interaction

Monitor/Modify Tx

ciprofloxacin + goserelin

monitor ECG, electrolytes, pseudotumor cerebri s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, intracranial HTN, papilledema (additive effects, androgen deprivation may prolong QT)

• guanfacine
Cipro (ciprofloxacin)

+

guanfacine

1 interaction

Monitor/Modify Tx

ciprofloxacin + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metab. inhibited)

• histrelin
Cipro (ciprofloxacin)

+

histrelin

1 interaction

Monitor/Modify Tx

ciprofloxacin + histrelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• hydrocortisone
Cipro (ciprofloxacin)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

ciprofloxacin + hydrocortisone

consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, incl. Cushing syndrome and adrenal suppression, other adverse effects; may incr. risk of tendon rupture (hepatic metab. inhibited; mechanism unknown)

• hydroxyzine
Cipro (ciprofloxacin)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

ciprofloxacin + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibrutinib
Cipro (ciprofloxacin)

+

ibrutinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + ibrutinib

B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• iloperidone
Cipro (ciprofloxacin)

+

iloperidone

1 interaction

Monitor/Modify Tx

ciprofloxacin + iloperidone

monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• imipramine
Cipro (ciprofloxacin)

+

imipramine

1 interaction

Monitor/Modify Tx

ciprofloxacin + imipramine

monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metab. inhibited)

• inotuzumab ozogamicin
Cipro (ciprofloxacin)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

ciprofloxacin + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• insulin
Cipro (ciprofloxacin)

+

insulin

1 interaction

Monitor/Modify Tx

ciprofloxacin + insulin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• iopamidol
Cipro (ciprofloxacin)

+

iopamidol

1 interaction

Monitor/Modify Tx

ciprofloxacin + iopamidol

caution advised if intrathecal iopamidol use; consider holding ciprofloxacin at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irinotecan
Cipro (ciprofloxacin)

+

irinotecan

1 interaction

Monitor/Modify Tx

ciprofloxacin + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metab. inhibited)

• isoflurane
Cipro (ciprofloxacin)

+

isoflurane

1 interaction

Monitor/Modify Tx

ciprofloxacin + isoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Cipro (ciprofloxacin)

+

itraconazole

1 interaction

Monitor/Modify Tx

ciprofloxacin + itraconazole

consider decr. itraconazole dose: combo may incr. itraconazole levels, risk of adverse effects (hepatic metab. inhibited)

• lanthanum
Cipro (ciprofloxacin)

+

lanthanum

1 interaction

Monitor/Modify Tx

ciprofloxacin + lanthanum

give oral ciprofloxacin at least 2h before or 6h after lanthanum dose; may skip lanthanum dose near time of oral ciprofloxacin admin. during short-course ciprofloxacin tx: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• lapatinib
Cipro (ciprofloxacin)

+

lapatinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + lapatinib

monitor ECG; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• leflunomide
Cipro (ciprofloxacin)

+

leflunomide

1 interaction

Monitor/Modify Tx

ciprofloxacin + leflunomide

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• leuprolide
Cipro (ciprofloxacin)

+

leuprolide

1 interaction

Monitor/Modify Tx

ciprofloxacin + leuprolide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lidocaine
Cipro (ciprofloxacin)

+

lidocaine

1 interaction

Monitor/Modify Tx

ciprofloxacin + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher w/ continuous infusion or higher doses for local anesthesia (hepatic metab. inhibited)

• linagliptin
Cipro (ciprofloxacin)

+

linagliptin

1 interaction

Monitor/Modify Tx

ciprofloxacin + linagliptin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• liraglutide
Cipro (ciprofloxacin)

+

liraglutide

1 interaction

Monitor/Modify Tx

ciprofloxacin + liraglutide

monitor glucose in type 2 diabetes mellitus pts, consider monitoring glucose in obesity pts: combo may decr. peak oral ciprofloxacin levels, efficacy; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (absorption delayed, possibly decreased; additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• lixisenatide
Cipro (ciprofloxacin)

+

lixisenatide

1 interaction

Monitor/Modify Tx

ciprofloxacin + lixisenatide

monitor glucose; give oral ciprofloxacin at least 1h before lixisenatide: combo may decr. peak ciprofloxacin levels, efficacy; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (absorption delayed, possibly decreased; additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• lofexidine
Cipro (ciprofloxacin)

+

lofexidine

1 interaction

Monitor/Modify Tx

ciprofloxacin + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lumateperone
Cipro (ciprofloxacin)

+

lumateperone

1 interaction

Monitor/Modify Tx

ciprofloxacin + lumateperone

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurasidone
Cipro (ciprofloxacin)

+

lurasidone

1 interaction

Monitor/Modify Tx

ciprofloxacin + lurasidone

monitor ECG; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• macimorelin
Cipro (ciprofloxacin)

+

macimorelin

1 interaction

Monitor/Modify Tx

ciprofloxacin + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• magnesium carbonate
Cipro (ciprofloxacin)

+

magnesium carbonate

1 interaction

Monitor/Modify Tx

ciprofloxacin + magnesium carbonate

give oral ciprofloxacin at least 2h before or 6h after magnesium carbonate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• magnesium citrate
Cipro (ciprofloxacin)

+

magnesium citrate

1 interaction

Monitor/Modify Tx

ciprofloxacin + magnesium citrate

give oral ciprofloxacin at least 2h before or 6h after magnesium citrate: combo may decr. ciprofloxacin levels, efficacy; may incr. risk of seizures (absorption decreased via chelation; additive effects)

• magnesium hydroxide
Cipro (ciprofloxacin)

+

magnesium hydroxide

1 interaction

Monitor/Modify Tx

ciprofloxacin + magnesium hydroxide

give oral ciprofloxacin at least 2h before or 6h after magnesium hydroxide: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• magnesium oxide
Cipro (ciprofloxacin)

+

magnesium oxide

1 interaction

Monitor/Modify Tx

ciprofloxacin + magnesium oxide

give oral ciprofloxacin at least 2h before or 6h after magnesium oxide: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• magnesium supplement
Cipro (ciprofloxacin)

+

magnesium supplement

1 interaction

Monitor/Modify Tx

ciprofloxacin + magnesium supplement

give oral ciprofloxacin at least 2h before or 6h after magnesium supplement: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• mavacamten
Cipro (ciprofloxacin)

+

mavacamten

1 interaction

Monitor/Modify Tx

ciprofloxacin + mavacamten

monitor cardiac fxn, incl. LVEF; if patient stable on ciprofloxacin tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) ciprofloxacin tx to existing mavacamten tx, hold mavacamten until ciprofloxacin D/C; if adding longer-term (>1wk) ciprofloxacin tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start ciprofloxacin tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Cipro (ciprofloxacin)

+

mavorixafor

1 interaction

Monitor/Modify Tx

ciprofloxacin + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mefloquine
Cipro (ciprofloxacin)

+

mefloquine

1 interaction

Monitor/Modify Tx

ciprofloxacin + mefloquine

monitor ECG: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• meropenem
Cipro (ciprofloxacin)

+

meropenem

1 interaction

Monitor/Modify Tx

ciprofloxacin + meropenem

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited)

• metformin
Cipro (ciprofloxacin)

+

metformin

1 interaction

Monitor/Modify Tx

ciprofloxacin + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, fluoroquinolones may alter blood glucose)

• mexiletine
Cipro (ciprofloxacin)

+

mexiletine

1 interaction

Monitor/Modify Tx

ciprofloxacin + mexiletine

titrate slowly; consider monitoring mexiletine levels: combo may incr. mexiletine levels, risk of adverse effects (hepatic metab. inhibited)

• midostaurin
Cipro (ciprofloxacin)

+

midostaurin

1 interaction

Monitor/Modify Tx

ciprofloxacin + midostaurin

monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• miglitol
Cipro (ciprofloxacin)

+

miglitol

1 interaction

Monitor/Modify Tx

ciprofloxacin + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects, fluoroquinolones may alter blood glucose)

• minocycline
Cipro (ciprofloxacin)

+

minocycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + minocycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• mirtazapine
Cipro (ciprofloxacin)

+

mirtazapine

1 interaction

Monitor/Modify Tx

ciprofloxacin + mirtazapine

monitor ECG: combo may incr. mirtazapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mitapivat
Cipro (ciprofloxacin)

+

mitapivat

1 interaction

Monitor/Modify Tx

ciprofloxacin + mitapivat

monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metab. inhibited)

• molindone
Cipro (ciprofloxacin)

+

molindone

1 interaction

Monitor/Modify Tx

ciprofloxacin + molindone

give oral ciprofloxacin at least 2h before or 6h after molindone: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation, molindone contains calcium)

• mycophenolate mofetil
Cipro (ciprofloxacin)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

ciprofloxacin + mycophenolate mofetil

monitor rejection s/sx: combo may decr. mycophenolic acid levels, efficacy (enterohepatic circulation altered)

• mycophenolic acid
Cipro (ciprofloxacin)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

ciprofloxacin + mycophenolic acid

monitor rejection s/sx: combo may decr. mycophenolic acid levels, efficacy (enterohepatic circulation altered)

• nateglinide
Cipro (ciprofloxacin)

+

nateglinide

1 interaction

Monitor/Modify Tx

ciprofloxacin + nateglinide

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• nifedipine
Cipro (ciprofloxacin)

+

nifedipine

1 interaction

Monitor/Modify Tx

ciprofloxacin + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nilotinib
Cipro (ciprofloxacin)

+

nilotinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + nilotinib

monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• nimodipine
Cipro (ciprofloxacin)

+

nimodipine

1 interaction

Monitor/Modify Tx

ciprofloxacin + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nitisinone
Cipro (ciprofloxacin)

+

nitisinone

1 interaction

Monitor/Modify Tx

ciprofloxacin + nitisinone

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• nortriptyline
Cipro (ciprofloxacin)

+

nortriptyline

1 interaction

Monitor/Modify Tx

ciprofloxacin + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metab. inhibited)

• olanzapine
Cipro (ciprofloxacin)

+

olanzapine

1 interaction

Monitor/Modify Tx

ciprofloxacin + olanzapine

consider decr. olanzapine dose: combo may incr. olanzapine levels, risk of adverse effects (hepatic metab. inhibited)

• omadacycline
Cipro (ciprofloxacin)

+

omadacycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + omadacycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• ondansetron
Cipro (ciprofloxacin)

+

ondansetron

1 interaction

Monitor/Modify Tx

ciprofloxacin + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Cipro (ciprofloxacin)

+

osilodrostat

1 interaction

Monitor/Modify Tx

ciprofloxacin + osilodrostat

monitor ECG: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• osimertinib
Cipro (ciprofloxacin)

+

osimertinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Cipro (ciprofloxacin)

+

pacritinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + pacritinib

monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• palbociclib
Cipro (ciprofloxacin)

+

palbociclib

1 interaction

Monitor/Modify Tx

ciprofloxacin + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• palonosetron
Cipro (ciprofloxacin)

+

palonosetron

1 interaction

Monitor/Modify Tx

ciprofloxacin + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Cipro (ciprofloxacin)

+

panobinostat

1 interaction

Monitor/Modify Tx

ciprofloxacin + panobinostat

monitor ECG, CBC: combo may incr. panobinostat levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• pasireotide
Cipro (ciprofloxacin)

+

pasireotide

1 interaction

Monitor/Modify Tx

ciprofloxacin + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• patiromer
Cipro (ciprofloxacin)

+

patiromer

1 interaction

Monitor/Modify Tx

ciprofloxacin + patiromer

separate admin. w/ oral ciprofloxacin by >3h: combo may decr. ciprofloxacin levels, efficacy (absorption decreased)

• pazopanib
Cipro (ciprofloxacin)

+

pazopanib

1 interaction

Monitor/Modify Tx

ciprofloxacin + pazopanib

monitor ECG: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pentamidine
Cipro (ciprofloxacin)

+

pentamidine

1 interaction

Monitor/Modify Tx

ciprofloxacin + pentamidine

monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• phenytoin
Cipro (ciprofloxacin)

+

phenytoin

1 interaction

Monitor/Modify Tx

ciprofloxacin + phenytoin

monitor phenytoin levels: combo may incr. or decr. phenytoin levels, incr. risk of adverse effects or decr. efficacy; may alter seizure control (mechanism unknown, hepatic metab. possibly altered; antagonistic effects, ciprofloxacin may decr. seizure threshold)

• pimavanserin
Cipro (ciprofloxacin)

+

pimavanserin

1 interaction

Monitor/Modify Tx

ciprofloxacin + pimavanserin

consider monitoring ECG: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pioglitazone
Cipro (ciprofloxacin)

+

pioglitazone

1 interaction

Monitor/Modify Tx

ciprofloxacin + pioglitazone

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• pirtobrutinib
Cipro (ciprofloxacin)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + pirtobrutinib

monitor CBC: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ponatinib
Cipro (ciprofloxacin)

+

ponatinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + ponatinib

monitor CBC: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• pramlintide
Cipro (ciprofloxacin)

+

pramlintide

1 interaction

Monitor/Modify Tx

ciprofloxacin + pramlintide

give oral ciprofloxacin at least 1h before or 2h after pramlintide; monitor glucose: combo may decr. peak ciprofloxacin levels, efficacy; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (absorption delayed/reduced; antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• pretomanid
Cipro (ciprofloxacin)

+

pretomanid

1 interaction

Monitor/Modify Tx

ciprofloxacin + pretomanid

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited)

• probenecid
Cipro (ciprofloxacin)

+

probenecid

1 interaction

Monitor/Modify Tx

ciprofloxacin + probenecid

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• propranolol
Cipro (ciprofloxacin)

+

propranolol

1 interaction

Monitor/Modify Tx

ciprofloxacin + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

• quetiapine
Cipro (ciprofloxacin)

+

quetiapine

1 interaction

Monitor/Modify Tx

ciprofloxacin + quetiapine

monitor ECG; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• quinapril
Cipro (ciprofloxacin)

+

quinapril

1 interaction

Monitor/Modify Tx

ciprofloxacin + quinapril

give oral ciprofloxacin at least 2h before or 6h after quinapril: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation, quinapril contains magnesium)

• quinidine (CYP2D6 inhibitor)
Cipro (ciprofloxacin)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

ciprofloxacin + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quinine
Cipro (ciprofloxacin)

+

quinine

1 interaction

Monitor/Modify Tx

ciprofloxacin + quinine

monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ranolazine
Cipro (ciprofloxacin)

+

ranolazine

1 interaction

Monitor/Modify Tx

ciprofloxacin + ranolazine

adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• rasagiline
Cipro (ciprofloxacin)

+

rasagiline

1 interaction

Monitor/Modify Tx

ciprofloxacin + rasagiline

adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metab. inhibited)

• red yeast rice
Cipro (ciprofloxacin)

+

red yeast rice

1 interaction

Monitor/Modify Tx

ciprofloxacin + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• repaglinide
Cipro (ciprofloxacin)

+

repaglinide

1 interaction

Monitor/Modify Tx

ciprofloxacin + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (hepatic metab. inhibited; additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• revumenib
Cipro (ciprofloxacin)

+

revumenib

1 interaction

Monitor/Modify Tx

ciprofloxacin + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Cipro (ciprofloxacin)

+

ribociclib

1 interaction

Monitor/Modify Tx

ciprofloxacin + ribociclib

monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• rifabutin
Cipro (ciprofloxacin)

+

rifabutin

1 interaction

Monitor/Modify Tx

ciprofloxacin + rifabutin

monitor CBC, uveitis s/sx: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects (hepatic metab. inhibited)

• rimegepant
Cipro (ciprofloxacin)

+

rimegepant

1 interaction

Monitor/Modify Tx

ciprofloxacin + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metab. inhibited)

• riociguat
Cipro (ciprofloxacin)

+

riociguat

1 interaction

Monitor/Modify Tx

ciprofloxacin + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metab. inhibited)

• romidepsin
Cipro (ciprofloxacin)

+

romidepsin

1 interaction

Monitor/Modify Tx

ciprofloxacin + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropinirole
Cipro (ciprofloxacin)

+

ropinirole

1 interaction

Monitor/Modify Tx

ciprofloxacin + ropinirole

consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of adverse effects (hepatic metab. inhibited)

• rosiglitazone
Cipro (ciprofloxacin)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

ciprofloxacin + rosiglitazone

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• rucaparib
Cipro (ciprofloxacin)

+

rucaparib

1 interaction

Monitor/Modify Tx

ciprofloxacin + rucaparib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib
Cipro (ciprofloxacin)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ruxolitinib topical
Cipro (ciprofloxacin)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

ciprofloxacin + ruxolitinib topical

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• sarecycline
Cipro (ciprofloxacin)

+

sarecycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + sarecycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• saxagliptin
Cipro (ciprofloxacin)

+

saxagliptin

1 interaction

Monitor/Modify Tx

ciprofloxacin + saxagliptin

monitor glucose: combo may incr. saxagliptin levels, risk of adverse effects; may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (hepatic metab. inhibited; antagonistic effects, additive effects; fluoroquinolones may alter blood glucose)

• sebetralstat
Cipro (ciprofloxacin)

+

sebetralstat

1 interaction

Monitor/Modify Tx

ciprofloxacin + sebetralstat

consider monitoring ECG; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• semaglutide
Cipro (ciprofloxacin)

+

semaglutide

1 interaction

Monitor/Modify Tx

ciprofloxacin + semaglutide

monitor glucose in type 2 diabetes mellitus pts; consider monitoring glucose in obesity pts: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects, fluoroquinolones may alter blood glucose)

• sertraline
Cipro (ciprofloxacin)

+

sertraline

1 interaction

Monitor/Modify Tx

ciprofloxacin + sertraline

monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• sevelamer
Cipro (ciprofloxacin)

+

sevelamer

1 interaction

Monitor/Modify Tx

ciprofloxacin + sevelamer

give oral ciprofloxacin at least 2h before or 6h after each sevelamer dose: combo may decr. ciprofloxacin levels, efficacy (absorption decreased/delayed)

• sevoflurane
Cipro (ciprofloxacin)

+

sevoflurane

1 interaction

Monitor/Modify Tx

ciprofloxacin + sevoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus
Cipro (ciprofloxacin)

+

sirolimus

1 interaction

Monitor/Modify Tx

ciprofloxacin + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited)

• sirolimus albumin-bound
Cipro (ciprofloxacin)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

ciprofloxacin + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• sitagliptin
Cipro (ciprofloxacin)

+

sitagliptin

1 interaction

Monitor/Modify Tx

ciprofloxacin + sitagliptin

monitor glucose: combo may alter glycemic control, incr. risk of hyperglycemia or severe hypoglycemia, incl. life-threatening (additive effects, antagonistic effects)

• somatropin
Cipro (ciprofloxacin)

+

somatropin

1 interaction

Monitor/Modify Tx

ciprofloxacin + somatropin

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• sparsentan
Cipro (ciprofloxacin)

+

sparsentan

1 interaction

Monitor/Modify Tx

ciprofloxacin + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (incl. orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• sucralfate
Cipro (ciprofloxacin)

+

sucralfate

1 interaction

Monitor/Modify Tx

ciprofloxacin + sucralfate

give oral ciprofloxacin at least 2h before or 6h after sucralfate: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)

• sulfate bowel prep
Cipro (ciprofloxacin)

+

sulfate bowel prep

1 interaction

Monitor/Modify Tx

ciprofloxacin + sulfate bowel prep

give oral ciprofloxacin at least 2h before or 6h after bowel prep: combo may decr. ciprofloxacin levels, efficacy; may incr. risk of seizures (absorption decreased via chelation, bowel prep contains magnesium; additive effects)

• sunitinib
Cipro (ciprofloxacin)

+

sunitinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + sunitinib

consider monitoring ECG, electrolytes: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• suvorexant
Cipro (ciprofloxacin)

+

suvorexant

1 interaction

Monitor/Modify Tx

ciprofloxacin + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• suzetrigine
Cipro (ciprofloxacin)

+

suzetrigine

1 interaction

Monitor/Modify Tx

ciprofloxacin + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• tacrolimus
Cipro (ciprofloxacin)

+

tacrolimus

1 interaction

Monitor/Modify Tx

ciprofloxacin + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• tadalafil
Cipro (ciprofloxacin)

+

tadalafil

1 interaction

Monitor/Modify Tx

ciprofloxacin + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• tamsulosin
Cipro (ciprofloxacin)

+

tamsulosin

1 interaction

Monitor/Modify Tx

ciprofloxacin + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• telavancin
Cipro (ciprofloxacin)

+

telavancin

1 interaction

Monitor/Modify Tx

ciprofloxacin + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• temsirolimus
Cipro (ciprofloxacin)

+

temsirolimus

1 interaction

Monitor/Modify Tx

ciprofloxacin + temsirolimus

monitor CBC; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• teriflunomide
Cipro (ciprofloxacin)

+

teriflunomide

1 interaction

Monitor/Modify Tx

ciprofloxacin + teriflunomide

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• tetrabenazine
Cipro (ciprofloxacin)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

ciprofloxacin + tetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tetracycline
Cipro (ciprofloxacin)

+

tetracycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + tetracycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• tigecycline
Cipro (ciprofloxacin)

+

tigecycline

1 interaction

Monitor/Modify Tx

ciprofloxacin + tigecycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• tirzepatide
Cipro (ciprofloxacin)

+

tirzepatide

1 interaction

Monitor/Modify Tx

ciprofloxacin + tirzepatide

monitor glucose if type 2 diabetes mellitus use: combo may decr. oral ciprofloxacin levels, efficacy; may decr. antidiabetic agent efficacy (absorption delayed, possibly decreased; antagonistic effects, fluoroquinolones may alter blood glucose)

• tofacitinib
Cipro (ciprofloxacin)

+

tofacitinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + tofacitinib

monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib dose as follows: RHEUMATOID or PSORIATIC ARTHRITIS: decr. tofacitinib dose to 5 mg qd; ULCERATIVE COLITIS: decr. tofacitinib 22 mg qd dose to 11 mg qd; decr. tofacitinib 11 mg qd dose to 5 mg qd; decr. tofacitinib 10 mg bid dose to 5 mg bid; decr. tofacitinib 5 mg bid dose to 5 mg qd; JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• trabectedin
Cipro (ciprofloxacin)

+

trabectedin

1 interaction

Monitor/Modify Tx

ciprofloxacin + trabectedin

monitor CBC, cardiac fxn, LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• trazodone
Cipro (ciprofloxacin)

+

trazodone

1 interaction

Monitor/Modify Tx

ciprofloxacin + trazodone

monitor ECG, BP: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• triazolam
Cipro (ciprofloxacin)

+

triazolam

1 interaction

Monitor/Modify Tx

ciprofloxacin + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• triclabendazole
Cipro (ciprofloxacin)

+

triclabendazole

1 interaction

Monitor/Modify Tx

ciprofloxacin + triclabendazole

monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• trifluridine
Cipro (ciprofloxacin)

+

trifluridine

1 interaction

Monitor/Modify Tx

ciprofloxacin + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethoprim
Cipro (ciprofloxacin)

+

trimethoprim

1 interaction

Monitor/Modify Tx

ciprofloxacin + trimethoprim

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• triptorelin
Cipro (ciprofloxacin)

+

triptorelin

1 interaction

Monitor/Modify Tx

ciprofloxacin + triptorelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• ubrogepant
Cipro (ciprofloxacin)

+

ubrogepant

1 interaction

Monitor/Modify Tx

ciprofloxacin + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• vaborbactam
Cipro (ciprofloxacin)

+

vaborbactam

1 interaction

Monitor/Modify Tx

ciprofloxacin + vaborbactam

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited)

• vadadustat
Cipro (ciprofloxacin)

+

vadadustat

1 interaction

Monitor/Modify Tx

ciprofloxacin + vadadustat

monitor ECG: combo may incr. ciprofloxacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport inhibited)

• vemurafenib
Cipro (ciprofloxacin)

+

vemurafenib

1 interaction

Monitor/Modify Tx

ciprofloxacin + vemurafenib

monitor ECG, electrolytes: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• vinblastine
Cipro (ciprofloxacin)

+

vinblastine

1 interaction

Monitor/Modify Tx

ciprofloxacin + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Cipro (ciprofloxacin)

+

vincristine

1 interaction

Monitor/Modify Tx

ciprofloxacin + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Cipro (ciprofloxacin)

+

vinorelbine

1 interaction

Monitor/Modify Tx

ciprofloxacin + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• voclosporin
Cipro (ciprofloxacin)

+

voclosporin

1 interaction

Monitor/Modify Tx

ciprofloxacin + voclosporin

monitor ECG, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• warfarin
Cipro (ciprofloxacin)

+

warfarin

1 interaction

Monitor/Modify Tx

ciprofloxacin + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, alteration of vitamin K producing gut flora)

• zanubrutinib
Cipro (ciprofloxacin)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

ciprofloxacin + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• zinc oral
Cipro (ciprofloxacin)

+

zinc oral

1 interaction

Monitor/Modify Tx

ciprofloxacin + zinc oral

give oral ciprofloxacin at least 2h before or 6h after oral zinc salts: combo may decr. ciprofloxacin levels, efficacy (absorption decreased via chelation)